Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + Chemotherapy vs Chemotherapy in KRAS Wild Type Pancreatic Cancer
NCT06998940Phase 3Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- May 2026
- Primary completion
- Dec 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of panitumumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by SWOG Cancer Research Network. Started May 2026; status: recruiting.
02
Drugs
panitumumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06998940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06998940.